IGCS 2022 Master Session: Ovarian Cancer-Master Session: Ovarian Cancer

Video Transcription

Video Summary

The video discusses the use of hyperthermia in cancer treatment, specifically focusing on its potential benefits in ovarian cancer. It highlights that while some cell lines are susceptible to cell death at 42 degrees Celsius, not all cells respond the same way and require different temperatures for heat exposure. It also mentions the synergy that can occur when hyperthermia is combined with cisplatin, increasing sensitivity to platinum-based chemotherapy. The video explores various hypotheses on why hyperthermia works, such as apoptosis, heat shock protein activation, DNA repair inhibition, T-cell infiltration, and increased blood flow, although more research is needed to prove these theories. <br /><br />The video then introduces heated intra-peritoneal chemotherapy (HIPC) for ovarian cancer, which uses cisplatin and carboplatin as main agents due to their high concentrations in the peritoneum. Several clinical studies on HIPC are discussed, noting that they have produced conflicting results. The speaker emphasizes the need for more data and ongoing studies to better understand the benefits and optimal use of HIPC in ovarian cancer treatment. The video concludes by mentioning the ongoing trial GOG3068, which aims to provide more answers about HIPC and its role as a standard of care in ovarian cancer treatment.

Keywords

hyperthermia

cancer treatment

ovarian cancer

cell death

heat exposure

cisplatin

platinum-based chemotherapy

apoptosis

heat shock protein activation

DNA repair inhibition

T-cell infiltration

increased blood flow

heated intra-peritoneal chemotherapy

peritoneum

clinical studies

conflicting results